About the Pancreatic Ductal Adenocarcinoma Session
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat, largely due to its aggressive nature and tendency for late-stage diagnosis. However, recent advancements in cancer research offer glimmers of hope. Novel immunotherapies, targeted therapies, and combination treatments are being investigated to combat PDAC's resistance to conventional therapies. Additionally, genomic profiling has unveiled potential biomarkers for early detection and personalized treatment strategies. Innovative techniques like liquid biopsies hold promise for non-invasive monitoring of disease progression. Collaborative efforts between researchers, clinicians, and pharmaceutical companies are driving forward momentum in understanding PDAC's complex biology and developing more effective interventions. While significant challenges persist, the evolving landscape of cancer research offers optimism for improving outcomes in pancreatic ductal adenocarcinoma patients.
Topics Covered in Pancreatic Ductal Adenocarcinoma
Molecular Subtypes
Desmoplastic Stroma
Cystic Precursor Lesions
Borderline Resectable Disease
KRAS Targeting
Liquid Biopsy
Related Scientific Sessions at CIOC 2027
Why Attend the Pancreatic Ductal Adenocarcinoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Pancreatic Ductal Adenocarcinoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Pancreatic Ductal Adenocarcinoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Pancreatic Ductal Adenocarcinoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Pancreatic Ductal Adenocarcinoma Conference 2027 — FAQs
What is the Pancreatic Ductal Adenocarcinoma track at CIOC 2027?
The Pancreatic Ductal Adenocarcinoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Pancreatic Ductal Adenocarcinoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Pancreatic Ductal Adenocarcinoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Pancreatic Ductal Adenocarcinoma are all welcome — whether presenting or attending.
Can I present my research in the Pancreatic Ductal Adenocarcinoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Pancreatic Ductal Adenocarcinoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Pancreatic Ductal Adenocarcinoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.